Equities research analysts expect Apricus Biosciences, Inc (NASDAQ:APRI) to report earnings per share of ($0.15) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Apricus Biosciences’ earnings. Apricus Biosciences reported earnings of ($0.19) per share during the same quarter last year, which indicates a positive year over year growth rate of 21.1%. The business is scheduled to issue its next earnings report on Tuesday, November 14th.

On average, analysts expect that Apricus Biosciences will report full-year earnings of ($0.81) per share for the current financial year. For the next year, analysts anticipate that the business will report earnings of $1.49 per share. Zacks’ EPS calculations are an average based on a survey of analysts that cover Apricus Biosciences.

Apricus Biosciences (NASDAQ:APRI) last released its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.01.

Several brokerages recently issued reports on APRI. Zacks Investment Research downgraded shares of Apricus Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Apricus Biosciences in a research note on Wednesday, August 30th.

WARNING: “Analysts Expect Apricus Biosciences, Inc (APRI) to Announce -$0.15 EPS” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/10/06/analysts-expect-apricus-biosciences-inc-apri-to-announce-0-15-eps.html.

Shares of Apricus Biosciences (NASDAQ:APRI) opened at 2.04 on Friday. The stock’s 50 day moving average is $1.67 and its 200 day moving average is $1.40. The stock has a market cap of $26.08 million, a price-to-earnings ratio of 3.41 and a beta of 0.52. Apricus Biosciences has a 52-week low of $0.26 and a 52-week high of $4.07.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Get a free copy of the Zacks research report on Apricus Biosciences (APRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.